Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*FREE
Publication: Annals of Internal Medicine
Volume 157, Number 1
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
Description:
Although approximately 85 million units of red blood cells (RBCs) are transfused annually worldwide, transfusion practices vary widely. The AABB (formerly, the American Association of Blood Banks) developed this guideline to provide clinical recommendations about hemoglobin concentration thresholds and other clinical variables that trigger RBC transfusions in hemodynamically stable adults and children.
Methods:
These guidelines are based on a systematic review of randomized clinical trials evaluating transfusion thresholds. We performed a literature search from 1950 to February 2011 with no language restrictions. We examined the proportion of patients who received any RBC transfusion and the number of RBC units transfused to describe the effect of restrictive transfusion strategies on RBC use. To determine the clinical consequences of restrictive transfusion strategies, we examined overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay.
Recommendation 1:
The AABB recommends adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients (Grade: strong recommendation; high-quality evidence).
Recommendation 2:
The AABB suggests adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less (Grade: weak recommendation; moderate-quality evidence).
Recommendation 3:
The AABB cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome (Grade: uncertain recommendation; very low-quality evidence).
Recommendation 4:
The AABB suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration (Grade: weak recommendation; low-quality evidence).
Approximately 15 million red blood cell (RBC) units are transfused annually in the United States (1); about 85 million are transfused annually worldwide (2). Although there are many potential reasons for the different RBC transfusion practices that exist throughout the world, one reason may be the limited high-quality evidence of the benefits and harms of RBC transfusions.
Physicians most commonly use hemoglobin concentration to decide when to transfuse (3). However, most guidelines (4, 5) emphasize that transfusion should be given for symptoms of anemia and should not be based on hemoglobin concentration alone.
Previous guidelines have identified patients with coronary artery disease as an important subgroup that may need to be treated differently. Oxygen delivery from RBCs to the heart is critical and may be reduced by obstructed coronary arteries or anemia. Animal (6–8) and human (9) studies indicate higher risk for death and complications associated with anemia in the presence of coronary artery disease. Hence, there is concern about withholding RBC transfusion in patients with ischemic cardiovascular disease.
Optimal use should involve administering enough RBCs to maximize clinical outcomes while avoiding unnecessary transfusions that increase costs and expose patients to potential infectious or noninfectious risks. The Figure depicts amounts of such risks and, to provide context, contrasts those amounts with other risks, such as motor vehicle fatalities. Because there is no reason to transfuse more RBCs unless doing so improves outcomes, a liberal transfusion strategy (use of higher hemoglobin thresholds) would be preferable only if evidence supports its superiority over a restrictive transfusion strategy (use of lower hemoglobin thresholds). Thus, restrictive transfusion is preferable if reliable evidence demonstrates either noninferiority or superiority to liberal transfusion.
Figure. Adverse effects of RBC transfusion contrasted with other risks.
Risk is depicted on a logarithmic scale. Shaded bars represent the risk per RBC unit transfused, and unshaded bars represent the risk for fatality per person per year for various life events. During 2007 through 2008, HIV incidence in blood donors was 3.1 per 100 000 person-years. Residual risk was estimated as 1:1 467 000 transfused blood components or 6.8 per 10 million transfused components (10). During 2007 through 2008, HCV incidence in blood donors was 5.1 per 100 000 person-years with residual risk estimate of 0.87 per million transfused blood components (1:1 149 000) or 8.7 per 10 million transfused components (10). For 2006 to 2008, HBV incidence in blood donors was 3.41 to 3.43 per 100 000 person-years. The estimated residual risk for HBV was 1 in 282 000 to 1 in 357 000 transfused blood components (11) or 2.8 per million to 3.6 per million transfused blood components. In a recently published, large, prospective study with active recipient surveillance, the rate of TRALI occurrence in 2009 was 0.81 (95% CI, 0.44 to 1.49) per 10 000 transfused blood components or 8.1 per 100 000 transfused blood components (12). Although the literature has a wide range of TRALI risk estimates (1, 13–16), we have selected the rate reported in this recent prospective study. Three studies of TACO have produced similar results. In a study of 901 intensive care unit patients, 6% of patients who received transfusions developed TACO. Median units transfused were 2 RBCs and 3 overall (including plasma and platelets) (17). The rate per transfused RBC unit was 2 to 3 per 100. In 382 patients undergoing hip and knee replacement, 1% developed TACO after surgery (18). In a study of patients having total hip and knee arthroplasty, 8% developed fluid overload necessitating diuretic use and 4% of patients who did not receive transfusions developed fluid overload, leading to a TACO estimate of 4% (19). In published studies from the late 1990s, the risk for fatal hemolysis was estimated to range from 1.3 to 1.7 per million (5.9 to 7.7 per 10 million) transfused RBC units in one report (20) and 1 per 1 800 000 or 8.5 per 10 million in a second report (21). More recently, transfusion-related fatalities due to hemolysis reported to the U.S. Food and Drug Administration averaged 12.5 deaths per year from 2005 to 2010 (22). With 15 million RBC units transfused per year, the estimated risk for death due to hemolysis is 1:1 250 000 or 8 per 10 million RBC units. Fever (febrile nonhemolytic transfusion reactions) was estimated to be 1.1% with prestorage leukoreduction and 2.15% with poststorage leukoreduction (23). Death from medical error as reported by the Institute of Medicine was 1.3 to 2.9 per 1000 hospital admissions (24). Life-threatening transfusion reactions, defined as reactions requiring major medical intervention (for example, vasopressors, intubation, or transfer to an intensive care unit), occurred in 1:139 908 transfusions or 7.1 per million transfusions (1). Fatal motor vehicle accidents were estimated at 13.1 per 100 000 persons in 2008 or 1.3 per 10 000 persons (25). The rate of firearm homicide (which excludes suicide) was 4 per 100 000 persons in 2008 (25). Fatal falls were estimated at 8.2 deaths per 100 000 persons in 2008 (25). Lightning fatalities ranged from 0.02 per million (2 per 100 million) persons in California and Massachusetts to 2.0 per million persons in Wyoming (0 risk in Hawaii, Rhode Island, and Alaska) (26). The odds of being killed on a single airline flight on the 30 airlines with the best accident rates were 1 per 29.4 million. Among the 25 airlines with the worst accident records, rates were 1.7 per million per flight (27). Modified from Dzik (2002) (28). HBV = hepatitis B virus; HCV = hepatitis C virus; RBC = red blood cell; TACO = transfusion-associated circulatory overload; TRALI = transfusion-related acute lung injury.
Many small trials have addressed the question of optimal use of RBC transfusions. Two reviews of the Cochrane database, including an update in 2010 that included all available trials published through August 2009, have summarized those data (29, 30). Recently, 2 additional trials were published that expanded by 30% the number of patients included in the evidence base of transfusion trials (31, 32). Thus, it is timely to reexamine the data and provide guidance to the medical community.
Guideline Focus
These guidelines focus on hemoglobin concentration thresholds and other clinical variables that might trigger RBC transfusion. Practice guidelines are not intended as standards or absolute requirements and do not apply to all individual transfusion decisions. Clinical judgment is critical in the decision to transfuse; therefore, transfusing RBCs above or below the specified hemoglobin threshold may be dictated by the clinical context. Similarly, the decision not to transfuse RBCs to a patient with a hemoglobin concentration below the recommended thresholds is also a matter of clinical judgment.
Target Population
These guidelines provide advice for hemodynamically stable adults and children who are candidates for RBC transfusions.
Guideline Development Process
The AABB (formerly, the American Association of Blood Banks) commissioned and funded these guidelines through the AABB Clinical Transfusion Medicine Committee. In addition, the AABB Board of Directors directed the committee to recruit experts with interest in RBC transfusion from other professional organizations.
Panel Composition
A committee of 20 experts was assembled. Twelve were current or former members of the AABB Clinical Transfusion Medicine Committee, whereas 6 were appointed by their respective professional organizations as subject matter experts. Fifteen of the physicians were pathologists or hematologists, most of whom had subspecialty expertise in transfusion medicine. The others included an anesthesiologist; a cardiologist; a pediatrician; experts in critical care medicine; trauma surgeons; specialists in internal medicine and systematic review; and a Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodologist. Committee members had no substantial conflicts of interest as defined by the AABB conflict of interest policy (33). Pursuant to the policy, individual members were required to disclose actual and apparent financial, professional, or personal conflicts.
Evidence Review and Grading
Systematic Review
We developed these guidelines on the basis of an updated systematic review of the literature on transfusion thresholds, which is separately published by the first author of this paper (30, 34). We searched the Cochrane Injuries Group Specialized Register, CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE from 1950 to the second week of August 2009, EMBASE from 1980 to the fourth week of 2011, SCI-EXPANDED (Science Citation Index Expanded) from 1970 to February 2011, and CPCI-S (Conference Proceedings Citation Index-Science) from 1990 to February 2011. There were no language restrictions. We received no external funding.
The systematic review included randomized, controlled trials in which the transfusion groups were assigned on the basis of a clear transfusion “trigger” or “threshold,” described as the hemoglobin level or hematocrit that had to be reached before transfusion of RBCs. Comparison group patients were required to have received transfusions with allogeneic or autologous RBCs at higher hemoglobin levels or hematocrits (transfusion threshold) than the intervention group. Alternatively, the control group could have received transfusions in accordance with current transfusion practices, which may not have included a well-defined threshold but involved liberal rather than restrictive transfusion practices. We included trials of surgical and medical patients involving adults and children. We did not examine adverse events related to transfusion. We also did not examine observational studies evaluating the effect of transfusion because such studies are especially prone to confounding by indication and may give biased results (35, 36).
The primary outcomes in the systematic review were the proportion of patients who received transfusions with allogeneic or autologous RBCs. Secondary outcomes included illness (nonfatal myocardial infarction, cardiac events, pulmonary edema, congestive heart failure, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion), death, hemoglobin levels (postoperative or postdischarge), length of hospital stay, and the number of units transfused.
We evaluated each clinical trial for the risk of bias in sequence generation, allocation concealment, blinding, and incomplete outcome data by using methods recommended by the Cochrane Collaboration (37). We examined statistical heterogeneity by using both the I 2 and chi-square tests (37). We performed all analyses by using Cochrane Collaboration Review Manager Software (The Nordic Cochrane Center, Copenhagen, Denmark). For each trial, we calculated the relative risk (RR) for allogeneic transfusion in the intervention group compared with the control group and the corresponding 95% CI by using the random-effects model (38).
Grading of Evidence
We used the GRADE methodology to develop these guidelines (39, 40) (Appendix 2). We prepared evidence profiles that display information on the effect of RBC transfusion in terms of benefits and harms for the most important clinical outcomes. The profiles also contained information on study limitations, consistency, directness, precision, and reporting bias. For each question or indication, the panel rated the importance of each outcome in influencing the decision to administer a transfusion to a patient. The outcomes were scored from 1 (not critical to making a decision) to 9 (critical to making a decision). The panel also rated the quality of evidence across all outcomes. The overall quality of the trials for each outcome was first assessed by 2 of the authors, after which a consensus of the entire panel was adopted. Each member of the panel was asked to make his or her final judgment on the strength of each recommendation and the overall quality of the body of evidence. The final quality rating and the strength of each recommendation were reached by consensus during an in-person meeting with the panel members.
Comments and Modification
The first author prepared the draft guideline document, which was modified and approved by all panel members and the AABB Clinical Transfusion Medicine Committee. Subsequently, the AABB Board of Directors reviewed and approved the guidelines.
Clinical Recommendations
Question 1
In hospitalized, hemodynamically stable patients, at what hemoglobin concentration should a decision to transfuse RBCs be considered?
Recommendations
The AABB recommends adhering to a restrictive transfusion strategy.
In adult and pediatric intensive care unit patients, transfusion should be considered at hemoglobin concentrations of 7 g/dL or less.
In postoperative surgical patients, transfusion should be considered at a hemoglobin concentration of 8 g/dL or less or for symptoms (chest pain, orthostatic hypotension or tachycardia unresponsive to fluid resuscitation, or congestive heart failure).
Quality of evidence: high; strength of recommendation: strong.
Evidence Summary
Nineteen trials (n = 6264 patients) meeting the inclusion criteria were identified (31, 32, 41–57). Transfusion outcomes are summarized in Table 1. Overall, 39% fewer patients received transfusions in the restrictive group than in the liberal group. The mean number of units of RBCs transfused was 1.19 units lower and the mean hemoglobin concentration before transfusion was 1.48 g/dL lower in the restrictive group. These findings confirm that a restrictive transfusion strategy leads to a clinically important reduction in RBC use and a lower mean hemoglobin concentration.
The effect of restrictive transfusion on clinical outcomes is described in Table 2. Thirty-day mortality was reported in 11 of 19 clinical trials (31, 32, 41–44, 47, 49, 50, 52, 53). The risk of bias was low for this outcome. Restrictive transfusion resulted in lower mortality than did liberal transfusion (RR, 0.85 [95% CI, 0.7 to 1.03]), although the finding was not statistically significant. The upper limit of the CI suggests that a liberal transfusion strategy is unlikely to result in a clinically important reduction in mortality. The ability to walk independently or length of hospital stay did not differ between the 2 groups. For all other outcomes that were evaluated, we found no evidence to suggest that patients were harmed by a restrictive transfusion strategy, although many of the outcomes evaluated were infrequent and a true difference between the groups may have been undetectable.
Rationale for Recommendations
Our recommendation is based on the evidence that restrictive transfusion is safe and associated with less blood use. Although transfusion triggers differed among trials, no results favored the liberal strategy; in fact, the 3 largest trials conclusively showed a lack of benefit with liberal transfusion. Therefore, it is unlikely that a beneficial effect of liberal transfusion was missed. Our choice of the specific hemoglobin triggers is based on results from individual trials. The recommendation of 7 g/dL in adult and pediatric intensive care unit patients is based on the TRICC (Transfusion Requirements in Critical Care) (50) and TRIPICU (Transfusion Strategies for Patients in Pediatric Intensive Care Units) (52) trials, in which 7 g/dL was the hemoglobin level used in the restrictive group. The recommendation of 8 g/dL or symptoms in postoperative surgical patients is based on the results of the FOCUS (Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair) trial (32). The restrictive strategy in this trial permitted transfusion if the postoperative hemoglobin concentration was less than 8 g/dL or if the patient had symptoms, defined as chest pain believed to be cardiac in origin, orthostatic hypotension or tachycardia unresponsive to fluid challenge, or congestive heart failure. The panel believed that these recommendations would probably apply to most postsurgical and medical patients, with the exception of those with the acute coronary syndrome. We also recommend restrictive transfusion in patients receiving predeposit, autologous RBCs.
Whether surgical or medical patients outside the critical care setting would tolerate hemoglobin concentrations to 7 g/dL, similar to intensive care unit patients, has not been directly evaluated. Also, these recommendations do not address preoperative transfusion because this decision must also consider expected blood loss associated with the surgical procedure.
Question 2
In hospitalized, hemodynamically stable patients with preexisting cardiovascular disease, at what hemoglobin concentration should a decision to transfuse RBCs be considered?
Recommendations
The AABB suggests adhering to a restrictive transfusion strategy.
Transfusion should be considered at a hemoglobin concentration of 8 g/dL or less or for symptoms (chest pain, orthostatic hypotension or tachycardia unresponsive to fluid resuscitation, or congestive heart failure).
Quality of evidence: moderate; strength of recommendation: weak.
Evidence Summary
Clinical trial data that directly address the subgroup of patients with underlying cardiovascular disease are limited. The FOCUS trial (32) included postoperative patients with cardiovascular disease and cardiovascular risk factors. Overall, there was no difference in functional recovery; mortality; or hospital complications of myocardial infarction, congestive heart failure, stroke, infection, or thromboembolism with a liberal or restrictive transfusion strategy. Although 63% of patients had coronary artery disease or cardiovascular disease, the published results do not provide findings in the subgroup of patients with cardiovascular disease only or in patients with coronary artery disease. The only exception was for the primary outcomes of walking independently or death at 60 days; there was no difference (RR, 0.99 [CI, 0.88 to 1.11]) (32) in outcomes between the 2 strategies, nor in results comparing patients who had cardiovascular disease with patients who had cardiovascular risk factors only. In the TRICC trial (50), 43% of patients had cardiovascular disease. A subgroup analysis of these patients found that mortality rates were identical but there was a trend toward increased mortality in patients with ischemic heart disease in the restrictive transfusion group.
Two trials comparing the risk for myocardial infarction from restrictive transfusion and liberal transfusion provided 60% of the data. The TRICC trial found a lower risk for myocardial infarction in the restrictive group than in the liberal group (RR, 0.25 [CI, 0.07 to 0.88]) (50). In contrast, FOCUS found a higher risk for myocardial infarction in the restrictive group than in the liberal group, although this finding was not statistically significant (RR, 1.65 [CI, 0.99 to 2.75]) (32). Combined data from 8 trials (including the TRICC and FOCUS trials) that evaluated risk for myocardial infarction did not find elevated risk (RR, 0.88 [CI, 0.38 to 2.04]); however, the comparison lacked statistical power and the trials could have missed a 2-fold higher risk for myocardial infarction associated with restrictive transfusion. Similar results were found when overall cardiac events were examined.
Three trials involving patients having cardiac surgery compared restrictive transfusion and liberal transfusion, and no difference was found in mortality or cardiac outcomes among these trials (31, 42, 51). Because these patients had undergone revascularization to bypass obstructed coronary arteries, the results may not be applicable to patients with uncorrected underlying coronary artery disease.
Rationale for Recommendations
The panel advised that physicians should consider transfusion when hemoglobin concentration is less than 8 g/dL or when symptoms are present because overall mortality was not adversely affected and use of fewer RBC transfusions reduces cost and risks for adverse effects of transfusion. However, there was some uncertainty about the risk for perioperative myocardial infarction associated with a restrictive transfusion strategy. There was moderate heterogeneity between the results of the 2 major trials, and they were not large enough to precisely define the risks and benefits of transfusion in this setting.
Question 3
In hospitalized, hemodynamically stable patients with the acute coronary syndrome, at what hemoglobin concentration should an RBC transfusion be considered?
Recommendations
The AABB cannot recommend for or against a liberal or restrictive RBC transfusion threshold. Further research is needed to determine the optimal threshold.
Quality of evidence: very low; strength of recommendation: uncertain.
Evidence Summary
The systematic review did not identify any clinical trials evaluating transfusion thresholds in patients with the acute coronary syndrome.
Rationale for Recommendations
Because of a lack of clinical data from randomized, controlled trials, we provide no recommendations about the appropriate hemoglobin transfusion threshold for patients with the acute coronary syndrome. The panel recognized that observational studies in patients with the acute coronary syndrome have been reported (58) but, because of uncontrolled confounding, believed that the evidence from these types of studies was insufficient to support clear recommendations. The panel recommended that 1 or more clinical trials be performed to inform clinicians when patients with the acute coronary syndrome should receive a transfusion.
Question 4
In hospitalized, hemodynamically stable patients, should transfusion be guided by symptoms rather than hemoglobin concentration?
Recommendations
The AABB suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration.
Quality of evidence: low; strength of recommendation: weak.
Evidence Summary
Only the FOCUS trial (32) incorporated symptoms into the decision to transfuse. In this trial, patients in the restrictive group received transfusions if hemoglobin concentration was less than 8 g/dL or if they were symptomatic (32). Patients were permitted, but not required, to receive transfusion for symptoms. Overall, transfusions for symptoms were reported in 15.7% of patients in the restrictive group versus 5.3% in the liberal group. There were no statistically significant differences for any outcome examined.
Rationale for Recommendations
Conventional wisdom, based on physiologic reasoning, indicates that patients with symptoms benefit from RBC transfusion. However, there are limited trial data addressing this issue. In the FOCUS trial, patients in the restrictive group, all of whom could receive transfusions if they were symptomatic, did not have worse outcomes in terms of 30-day mortality or function than those who received transfusions at a hemoglobin threshold of 10 g/dL. Although patients with symptoms were not required to receive transfusions, withholding transfusion would be expected to increase adverse events in the restrictive group. Therefore, the results of this trial support the idea that transfusion should be guided by symptoms for patients with hemoglobin concentrations of 8 g/dL or greater rather than at a higher threshold.
Because transfusion was permitted in the FOCUS trial for patients with hemoglobin concentrations below 8 g/dL, no recommendations can be made about the use of symptoms to guide transfusion below this threshold.
The optimal trial would compare patients receiving transfusions based on hemoglobin concentration with those receiving transfusions only for symptoms. The panel believes that although such a trial would be valuable, it would probably require blinding physicians to the hemoglobin concentration, which raises issues of feasibility. Furthermore, there is probably a lack of clinical equipoise about transfusion in symptomatic patients. Thus, it is unlikely that such a trial will be done.
Discussion
Transfusion of RBCs is a common therapeutic intervention for which variation in clinical practice is considerable. Large observational studies have shown important differences in management of critical care (59–61), orthopedic surgery (13, 59), and cardiovascular surgery (14, 59) patients. On the basis of data from all of the available randomized trials, the panel found little evidence to support a liberal transfusion strategy. The restrictive transfusion thresholds used in the 3 largest randomized, controlled trials were 7 g/dL (50, 52) and 8 g/dL (32). Given these data, the panel recommended (strong recommendation) a restrictive transfusion strategy that uses these thresholds in most patient populations (hemodynamically stable critical care, surgical, and medical). For patients with cardiovascular disease, the panel also suggested (weak recommendation) a restrictive transfusion strategy because 1 large clinical trial (FOCUS) showed a statistically nonsignificant increase in myocardial infarction in the restrictive transfusion group but not an increase in mortality. For patients with the acute coronary syndrome, evidence was not sufficient to make specific recommendations.
If a restrictive transfusion strategy were widely implemented and replaced a liberal strategy, exposure of patients to RBC transfusions would decrease by an average of approximately 40% (RR, 0.61 [CI, 0.52 to 0.72]). This would have a large effect on blood use and the risks for infectious and noninfectious complications of transfusion.
Comparison With Other Guidelines
Previously published guidelines for the use of RBC transfusions, including those from the American Society of Anesthesiologists task force (4), the British Committee for Standards in Haematology (15), and the Australian and New Zealand Society of Blood Transfusion (16), have provided general recommendations for appropriate hemoglobin transfusion thresholds (transfusion is generally not indicated when the hemoglobin concentration is above 10 g/dL but is indicated when it is less than 6 to 7 g/dL). However, none of these guidelines recommended a specific transfusion trigger. Recent guidelines recommended a restrictive strategy (transfusion when the hemoglobin level is less than 7 g/dL) for adult trauma and critical care patients, with the exception of those with acute myocardial ischemia (62). Furthermore, these guidelines recommended avoiding transfusion based only on a hemoglobin trigger. Instead, the decision should be guided by such individual factors as bleeding, cardiopulmonary status, and intravascular volume. In contrast, the European Society of Cardiology has recommended withholding transfusion in patients with the acute coronary syndrome unless the hemoglobin concentration decreases to below 8 g/dL (63).
In contrast to the guidelines discussed, in the current guidelines, we explicitly used an evidence-based process that employed the GRADE method. The addition of new data from recently published clinical trials allowed for specific recommendations about transfusion thresholds. Although individual clinical factors are important, hemoglobin level is one of the critical elements used daily by physicians in the decision to transfuse. Thus, specific evidence-based recommendations on use of hemoglobin levels will help standardize transfusion practice.
Research Recommendations
The strength of the recommendations included in these guidelines is limited by the paucity of clinical trial data in certain patient populations. The results of the 3 largest trials (TRICC [50], TRIPICU [52], and FOCUS [32]) have not been replicated and do not include patients from many other populations who frequently receive transfusions. Clinical trials are needed in other patient populations that include (but are not limited to) patients with the acute coronary syndrome, elderly medical patients recovering from illnesses that result in hospitalization, patients with gastrointestinal bleeding, transfusion-dependent patients, patients with coagulopathy or hemorrhagic shock, and patients with traumatic brain injury. Furthermore, trials are needed to examine lower transfusion thresholds (for example, 6 g/dL), because the current evidence has examined thresholds of 7 g/dL in intensive care unit patients and 8 g/dL in other populations. This relative lack of clinical trial data is a barrier to wider acceptance of these guidelines.
Most of the important potential harms of transfusions are too infrequent to be detected by the evidence that we reviewed, and additional studies and reviews are needed to address this question.
Clinicians make decisions every day with incomplete evidence. We believe these guidelines provide a carefully considered set of recommendations that incorporate the quality of the evidence, benefits and risks of transfusion, and joint judgment of an expert panel from many subspecialties. More definitive recommendations await further clinical trials.
Appendix 1: Members of the AABB Guideline Group
Jeffrey L. Carson, MD (Chair), UMDNJ–Robert Wood Johnson Medical School, New Brunswick, New Jersey; Joanne L. Becker, MD, Roswell Park Cancer Institute, Buffalo, New York; Mark K. Fung, MD, PhD, Fletcher Allen Health Care, Burlington, Vermont; Brenda J. Grossman, MD, MPH, Washington University School of Medicine, Saint Louis, Missouri; John B. Holcomb, MD, University of Texas Medical Center at Houston, Houston, Texas; Leslie Holness, MD, U.S. Food and Drug Administration, Silver Spring, Maryland; Orieji Illoh, MD, U.S. Food and Drug Administration, Silver Spring, Maryland; Lewis J. Kaplan, MD, Yale Medical Group, New Haven, Connecticut; Louis M. Katz, MD, University of Iowa, Davenport, Iowa; Steven Kleinman, MD, AABB, Bethesda, Maryland; Marisa B. Marques, MD, University of Alabama at Birmingham, Birmingham, Alabama; Lisa Grace Swinton McLaughlin, MD, American Red Cross, Rockville, Maryland; Sunil V. Rao, MD, Duke University School of Medicine, Durham, North Carolina; John D. Roback, MD, PhD, Emory University School of Medicine, Atlanta, Georgia; Aryeh Shander, MD, Englewood Hospital and Medical Center, Englewood, New Jersey; Alan T. Tinmouth, MD, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Aaron A.R. Tobian, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, Maryland; Robert Weinstein, MD, University of Massachusetts Medical School, Worcester, Massachusetts; Benjamin Djulbegovic, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Eleftherios C. Vamvakas, MD, PhD, Cedars Sinai Medical Center, Los Angeles, California; Theresa Wiegmann, JD, AABB, Bethesda, Maryland; and Aaron Lyss, AABB, Bethesda, Maryland.
Appendix 2: GRADE Methodology
The GRADE system (39) uses the following 4 ratings for quality of evidence:
“High” indicates considerable confidence in the estimate of effect. The true effect probably lies close to the estimated effect, and future research is unlikely to change the estimate of the health intervention's effect.
“Moderate” indicates confidence that the estimate is close to the truth. Further research is likely to have an important effect on confidence in the estimate and may change the estimate of the health intervention's effect.
“Low” indicates that confidence in the effect is limited. The true effect may differ substantially from the estimate, and further research is likely to have an important effect on confidence in the estimate of the effect and is likely to change the estimate.
“Very low” indicates little confidence in the effect estimate. Any estimate of effect is very uncertain.
The strength of recommendations (for or against intervention) is graded as “strong” (indicating judgment that most well-informed people will make the same choice; “We recommend ...”), “weak” (indicating judgment that a majority of well-informed people will make the same choice, but a substantial minority will not; “We suggest ... ”), or “uncertain” (indicating that the panel made no specific recommendation for or against interventions; “We cannot recommend ... ”). The panel was instructed that 4 factors should play a role in making a recommendation: quality of evidence, uncertainty about the balance between desirable (benefits) and undesirable effects (harms), uncertainty or variability in values and preferences, and practice setting or uncertainty about whether the intervention represents a wise use of resources (costs).
The GRADE system considers 4 major factors in determination of the strength of recommendations: quality of evidence, balance between desirable (benefits) and undesirable (harms) outcomes, resource use and setting, and patient preferences and values. Although strong recommendations in favor of or against health care intervention typically reflect high-quality evidence, GRADE allows a strong recommendation to be made even if the quality of evidence is not high if other factors support such a recommendation.
References
1.
U.S. Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington, DC: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health; 2011.
2.
Takei T, Amin NA, Schmid G, Dhingra-Kumar N, Rugg D. Progress in global blood safety for HIV. J Acquir Immune Defic Syndr. 2009;52 Suppl 2 S127-31. [PMID: 19901625]
3.
Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion. 2010;50:2117-24. [PMID: 20492612]
4.
Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732-47. [PMID: 8659805]
5.
Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, et al; American College of Critical Care Medicine of the Society of Critical Care Medicine. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med. 2009;37:3124-57. [PMID: 19773646]
6.
Anderson HT, Kessinger JM, McFarland WJ Jr, Laks H, Geha AS. Response of the hypertrophied heart to acute anemia and coronary stenosis. Surgery. 1978;84:8-15. [PMID: 149386]
7.
Hagl S, Heimisch W, Meisner H, Erben R, Baum M, Mendler N. The effect of hemodilution on regional myocardial function in the presence of coronary stenosis. Basic Res Cardiol. 1977;72:344-64. [PMID: 901378]
8.
Wilkerson DK, Rosen AL, Sehgal LR, Gould SA, Sehgal HL, Moss GS. Limits of cardiac compensation in anemic baboons. Surgery. 1988;103:665-70. [PMID: 3375993]
9.
Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055-60. [PMID: 8874456]
10.
Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495-504. [PMID: 20345570]
11.
Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion. 2009;49:1609-20. [PMID: 19413732]
12.
Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al; for the TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119:1757-1767. [PMID: 22117051]
13.
Use of blood products for elective surgery in 43 European hospitals. The Sanguis Study Group. Transfus Med. 1994;4:251-68. [PMID: 7889138]
14.
Bennett-Guerrero E, Zhao Y, O'Brien SM, Ferguson TB Jr, Peterson ED, Gammie JS, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA. 2010;304:1568-75. [PMID: 20940382]
15.
Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113:24-31. [PMID: 11328275]
16.
National Health and Medical Research Council/Australasian Society of Blood Transfusion. Clinical Practice Guidelines: Appropriate Use of Red Blood Cells. Sydney, Australia: National Health and Medical Research Council/Australasian Society of Blood Transfusion; 2001.
17.
Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion. 2011;51:338-43. [PMID: 20723173]
18.
Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology. 1996;12:87-9. [PMID: 15387748]
19.
Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2-10. [PMID: 9973048]
20.
Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities [Letter]. Transfusion. 1997;37:243-4. [PMID: 9051106]
21.
Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion. 2000;40:1207-13. [PMID: 11061857]
22.
U.S. Food and Drug Administration. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2010. Silver Spring, MD: U.S. Food and Drug Administration; 2011.
23.
Federowicz I, Barrett BB, Andersen JW, Urashima M, Popovsky MA, Anderson KC. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion. 1996;36:21-8. [PMID: 8607149]
24.
Kohn L. To err is human: an interview with the Institute of Medicine's Linda Kohn. Jt Comm J Qual Improv. 2000;26:227-34. [PMID: 10749007]
25.
Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final Data for 2008. Hyattsville, MD: National Center for Health Statistics; 2011.
26.
Holle RL. Lightning Fatalities, Injuries, and Damage Reports in the United States. Louisville, CO: National Lightning Safety Institute; 2011. Accessed at www.lightningsafety.com/nlsi_lls/fatalities_us.html on 12 March 2012.
27.
Odds of being involved in fatal accident. PlaneCrashInfo.com. Accessed at www.planecrashinfo.com/cause.htm on 12 March 2012.
28.
Dzik WH. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion. 2003;43:1190-9. [PMID: 12919420]
29.
Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2002;:CD002042. [PMID: 12076437]
30.
Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2010;:CD002042. [PMID: 20927728]
31.
Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304:1559-67. [PMID: 20940381]
32.
Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365:2453-62. [PMID: 22168590]
33.
AABB. AABB Policy on Conflicts of Interest and Confidentiality. Bethesda, MD: AABB; 2006.
34.
Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;:CD002042.
35.
MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455-62. [PMID: 11273081]
36.
Middelburg RA, van de Watering LM, van der Bom JG. Blood transfusions: good or bad? Confounding by indication, an underestimated problem in clinical transfusion research. Transfusion. 2010;50:1181-3. [PMID: 20456689]
37.
Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Accessed at www.cochrane-handbook.org on 12 March 2012.
38.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
39.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. [PMID: 18436948]
40.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. [PMID: 15205295]
41.
Blair SD, Janvrin SB, McCollum CN, Greenhalgh RM. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg. 1986;73:783-5. [PMID: 3533203]
42.
Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion. 1999;39:1070-7. [PMID: 10532600]
43.
Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg. 1997;174:143-8. [PMID: 9293831]
44.
Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 1998;38:522-9. [PMID: 9661685]
45.
Colomo A, Hernandez-Gea V, Madoz P, Carles A, Alvarez-Urturi C, Poca M, et al. Hemodynamic changes and transfusion strategies in cirrhotic patients with acute variceal bleeding. Hepatology. 2009;50 Suppl 4 403A.
46.
Fortune JB, Feustel PJ, Saifi J, Stratton HH, Newell JC, Shah DM. Influence of hematocrit on cardiopulmonary function after acute hemorrhage. J Trauma. 1987;27:243-9. [PMID: 3560265]
47.
Foss NB, Kristensen MT, Jensen PS, Palm H, Krasheninnikoff M, Kehlet H. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion. 2009;49:227-34. [PMID: 19389209]
48.
Grover M, Talwalkar S, Casbard A, Boralessa H, Contreras M, Boralessa H, et al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang. 2006;90:105-12. [PMID: 16430668]
49.
Hébert PC, Wells G, Marshall J, Martin C, Tweeddale M, Pagliarello G, et al. Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group. JAMA. 1995;273:1439-44. [PMID: 7723158]
50.
Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409-17. [PMID: 9971864]
51.
Johnson RG, Thurer RL, Kruskall MS, Sirois C, Gervino EV, Critchlow J, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg. 1992;104:307-14. [PMID: 1495291]
52.
Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al; TRIPICU Investigators. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609-19. [PMID: 17442904]
53.
Lotke PA, Barth P, Garino JP, Cook EF. Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. J Arthroplasty. 1999;14:647-50. [PMID: 10512433]
54.
So-Osman C, Nelissen R, Te Slaa R, Coene L, Brand R, Brand A. A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells. Vox Sang. 2010;98:56-64. [PMID: 19656349]
55.
Fisher MR, Topley E. The illness of trauma. Br J Clin Pract. 1956;10:770-6. [PMID: 13374186]
56.
Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion. 2008;48:81-91. [PMID: 17894791]
57.
Zygun DA, Nortje J, Hutchinson PJ, Timofeev I, Menon DK, Gupta AK. The effect of red blood cell transfusion on cerebral oxygenation and metabolism after severe traumatic brain injury. Crit Care Med. 2009;37:1074-8. [PMID: 19237920]
58.
Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667-74. [PMID: 18679112]
59.
Hutton B, Fergusson D, Tinmouth A, McIntyre L, Kmetic A, Hébert PC. Transfusion rates vary significantly amongst Canadian medical centres. Can J Anaesth. 2005;52:581-90. [PMID: 15983142]
60.
Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al; ABC (Anemia and Blood Transfusion in Critical Care) Investigators. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499-507. [PMID: 12243637]
61.
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT Study: Anemia and blood transfusion in the critically ill—current clinical practice in the United States. Crit Care Med. 2004;32:39-52. [PMID: 14707558]
62.
Napolitano LM, Kurek S, Luchette FA, Anderson GL, Bard MR, Bromberg W, et al; EAST Practice Management Workgroup. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. J Trauma. 2009;67:1439-42. [PMID: 20009700]
63.
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-660. [PMID: 17569677]
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 157 • Number 1 • 3 July 2012
Pages: 49 - 58
History
Published online: 3 July 2012
Published in issue: 3 July 2012
Keywords
- Biochemistry
- Blood cells
- Cardiology and cardiovascular diseases
- Cardiovascular diseases
- Cell biology
- Cells
- Clinical trials
- Cognitive psychology
- Coronary heart disease
- Drug research and development
- Heart diseases
- Hemoglobin
- Hospital medicine
- Mortality
- Myocardial infarction
- Pharmacology
- Population statistics
- Prevention, policy, and public health
- Proteins
- Psychiatry and mental health
- Psychology
- Red blood cells
- Research and reporting methods
- Research assessment
- Vascular diseases
- Vascular medicine
- Vital statistics
Copyright
© 2012 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Ann Intern Med.2012;157:49-58. [Epub 3 July 2012]. doi:10.7326/0003-4819-157-1-201206190-00429
Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Ann Intern Med.2012;157:49-58. [Epub 3 July 2012]. doi:10.7326/0003-4819-157-1-201206190-00429
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Author's Response
We appreciate the opportunity to reiterate that our guidelines state that transfusion be CONSIDERED in specific patient subgroups when the nadir hemoglobin reaches 7-8 g/dL.(1) In addition, the decision to transfuse should be influenced by signs and symptoms. We based our recommendations on the best available evidence: 19 randomized clinical trials in 6,264 patients. However, clinical trials provide an average effect in the population studied. Thus, it is likely that some patients need more or less blood to improve outcomes. The “conundrum” is what clinical factors should influence the “routine titrated” transfusion decision. The largest trial evaluating transfusion thresholds used pre-specified symptoms (e.g., chest pain, orthostatic hypotension or tachycardia unresponsive to fluid resuscitation),(2) which we included in our guidelines. While this approach is based on a randomized trial, these symptoms will not be applicable to all clinical settings. We agree with the editorial accompanying the guidelines that other parameters such as fatigue, dyspnea, mechanical ventilation, or the use of low SvO2 (venous oxygen saturation) are unproven.(3)Unfortunately, there is no evidence to support other “important individual patient laboratory and physiological variables” as the basis for transfusion decisions. Drs. Klein and Natanson suggest that clinical trials evaluating transfusion thresholds should include an arm where patients are managed using the standard of care, which, in their opinion, is individually titrated transfusions. While it is true that this approach is often recommended, the evidence strongly suggests that clinicians do not follow this recommendation and have not adopted this approach as standard of care. For example, a recent study in orthopedic surgery documents that transfusion decisions were mostly based on hemoglobin levels.(4) Similarly, a study conducted in patients undergoing percutaneous coronary intervention showed that most transfusions were given when the hemoglobin dropped to a certain threshold, rather than for individual clinical circumstances. (5) This is also consistent with our anecdotal observations at our own hospitals. Given that most clinicians do not individually titrate transfusions, the proposed design would be very difficult to implement and would not reflect “real-world” practice. A more clinically applicable trial design incorporates pre-specified symptoms for transfusion along with hemoglobin thresholds. We stand by our recommendations: in pre-specified groups of patients, randomized clinical trials have demonstrated that restrictive transfusion using 7-8 g/dL threshold reduces blood use without harm. When this hemoglobin level is reached, we recommend considering transfusion, but only after evaluating the patient’s clinical status. Jeffrey L Carson, MDSunil V Rao, MDLouis M Katz, MD
References
1. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of internal medicine. 2012;157(1):49-58.
2. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. The New England journal of medicine. 2011;365(26):2453-62.
3. Vincent JL. Indications for blood transfusions: too complex to base on a single number? Annals of internal medicine. 2012;157(1):71-2.
4. Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion. 2010;50(10):2117-24.
5. Moscucci M, Ricciardi M, Eagle KA, Kline E, Bates ER, Werns SW, et al. Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions. The American journal of cardiology. 1998;81(6):702-7.
A Conundrum
The AABB’s recommendation, adhering to a “restrictive” transfusion threshold that relies on a hemoglobin determination of 7-8 gm/dL or less for hemodynamically stable patients, is well-intentioned, but problematic.(1) We are not surprised that the editorial accompanying this proposed new guideline arrives at a different conclusion.(2) We concur. We too believe that transfusion thresholds should be titrated based on many important individual patient laboratory and physiological variables. Why the disparity after considering the same decade of clinical experience and trial data? The weaknesses of the most influential trial are well described in the accompanying editorial. Since this and other trials upon which the AABB guideline committee based their recommendations never tested routine titrated care, the standard of care at the time, the trials could not determine whether either treatment – two arbitrarily selected hemoglobin determinations defined as “restrictive” or “liberal”- improved outcome or saved blood.(3) This trial design allows one to conclude only which of these two strategies should not be used. The less harmful treatment could still be worse than usual titrated care. The patients in this trial had a mortality risk of approximately 2/1000 or 0.2% per unit of transfused red blood cells, a death rate from transfusion some two orders of magnitude greater than that estimated at the time by the General Accounting Office for usual transfusion practice (0.001% or one death for every 10,000 units of transfused blood).(4) Differences in patient mix and follow-up seem unlikely to explain this enormous discrepancy. There is a real possibility that the new AABB guidelines have come to the wrong conclusion. We recognize that Carson et al. have softened their recommendations by acknowledging that “clinical judgment is critical in the decision to transfuse … transfusing RBCs above or below the specified hemoglobin threshold may be dictated by the clinical context.” We hope that this sentence will not be overlooked by those who seek a simple protocol-driven care approach. We do not believe that their systematic review provides sufficient direct evidence to change the previous recommendations by AABB and others regarding titrated transfusion practice. We concur with the authors’ observation that “clinical trials are needed in other patient populations.” However randomized, controlled trials with the addition of a titrated care arm in each of the conditions they describe are neither practical nor affordable. Since expert clinicians now appear to recognize more than one “standard of care” for red cell transfusion, the time is ripe to undertake comparative effectiveness trials using real world data and large populations to help resolve this conundrum. (5)
References
(1) Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B; for the Clinical Transfusion Medicine Committee of the AABB. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB Ann Intern Med. 2012;157(1):49-58
(2) Vincent JL. Indications for blood transfusions: too complex to base on a single number? Ann Intern Med. 2012;157(1):71-2
(3) Deans KJ, Minneci PC, Suffredini AF, Danner RL, Hoffman WD, Ciu X, Klein HG, Schechter AN, Banks SM, Eichacker PQ, Natanson C. Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med. 2007;35(6):1509-16
(4) United States General Accounting Office. Blood Supply: Transfusion- Associated Risks. 1997, Washington DC, GAO/PEMD-97-2
(5) Klein HG. Comparative effectiveness research: welcome to the real world. Transfusion. 2012; 52(6):1162-4
TRANSFUSION TRIGGERS point is how much effective?
Thanks to all authors and AARB for such a beautiful updated recommendation. Since beginning of my hospitalist carrier, every time I have been thinking are we over utilizing our resources regarding blood transfusion. From observation I have seen physician transfusing blood at number he/or she does not feel comfortable. Well known terms as "transfusion triggers differed among physician". I have been encouraging my resident group that don't learn what your attending wants, try to look for evidence behind it. I guess this new update will be great resource for me to teach my resident group. Again I would love to see more study regarding cost-effectiveness too. Since we are in the era of going through medical reforming, cost cutting, preventing readmission to save money. Can we save really reasonable amount of money avoiding aggressive blood transfusion. Now a days lot of talk going on regarding , cardiovascular disease, MI, CHF, infection (pneumonia), readmission, cutting payment by insurance providers. Surprisingly all these medical conditions was evaluated in different Blood transfusion study, such as FOCUS trial, TRICC study. Wondering, are we contributing or provocation some way by doing blood transfusion in this group of pt , when they come to hospital with borderline hb of 7-8, and receive blood transfusion along with Rx for admitted condition (PNA/MI/CHF etc). Hope to see in near future readmission group of pt with blood transfusion association from any trials for further evidence that will help to make clear decision. Not sure current recommendation with "TRANSFUSION TRIGGERS" point is how much effective. Rewarding Physician/hospital for less blood transfusion by insurance provider also might be very encouraging.
Conflict of Interest:None declared